Pharma BD Deal Intelligence
Novartis paid roughly $5.7B all-in for Chiron in 2006, but the vaccines franchise it was built around chronically lost money, forcing a $1.1B impairment and dismantling via three separate divestitures by 2015. Only the biopharma piece (Proleukin, TOBI) delivered durable value.
Novartis paid ~$5.7B for Chiron in 2006; the vaccines business it was built around chronically lost money, took a $1.1B impairment in 2014, and was dismantled via three separate divestitures by 2015 — the biopharma piece (Proleukin, TOBI) was the only durable value.
Full analysis, sources & comparables →Analysts initially questioned whether Novartis' $40/share offer was sufficient; the raised $45 bid brought the deal in line with sector valuation comparables.
An analyst called the $45/share bid 'a relatively good deal' but noted Chiron faces 'a number of challenges which have to be addressed,' particularly…
Novartis closed the Chiron deal at $5.1 billion and immediately stood up a new Vaccines & Diagnostics division, targeting $200 million in annual cost synergies…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Novartis announces deal to acquire remaining ~58% stake in Chiron at $45/share cash for ~$5.1B; gains influenza/vaccine franchise. Closed April 2006.
Novartis paid ~$5.7B for Chiron in 2006; the vaccines business it was built around chronically lost money, took a $1.1B impairment in 2014, and was dismantled via three separate divestitures by 2015 — the biopharma piece (Proleukin, TOBI) was the only durable value.
Assessment window: 15yr post-close.
30M US cases/yr · $1.7B Chiron 2004 total revenue (vaccines + blood testing + biopharma)
Influenza vaccines protect against seasonal flu strains updated annually by WHO; meningococcal vaccines prevent invasive Neisseria meningitidis infection. Blood nucleic acid testing (NAT) screens donor blood for HIV, HCV, and HBV at the viral RNA level, dramatically shortening the infectious window vs antibody tests.
In 2005, the global vaccines market was dominated by Sanofi Pasteur (Fluzone, Menactra), GlaxoSmithKline (Fluarix, Infanrix, Boostrix), Merck (M-M-R II, Gardasil pipeline), and Wyeth/Lederle (Prevnar). Chiron was the #5 global vaccine producer and #2 US flu supplier (Fluvirin), but had been crippled in October 2004 when UK regulators suspended its Liverpool plant for Serratia marcescens contamination, wiping out half the US flu supply that season. Menjugate was Chiron's lead meningococcal C conjugate vaccine, competing with Sanofi's Menactra. Chiron's Procleix nucleic acid blood-screening assays competed with Roche/Gen-Probe's Cobas TaqScreen. Biopharmaceuticals included Proleukin (IL-2 for metastatic RCC/melanoma), TOBI (inhaled tobramycin for cystic fibrosis), and co-marketed Betaseron (interferon beta-1b for MS). The deal gave Novartis its first vaccines franchise, building a new Vaccines & Diagnostics division to compete with Sanofi-Aventis, GSK, and Merck. Novartis paid $45/share — a 23% premium over the unaffected price — after raising from an initial rejected $40 bid. Source: https://www.swissinfo.ch/eng/novartis-buys-vaccine-maker-chiron/4817652
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Chiron Corporation (this deal) | 2005 | $5.1B | 36 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2005 deals · Novartis AG deals